| Some experts expressed pancreatic cancer medication caution about the study, noting its lack of controls or clinical end points. (Nissen SE et al. JAMA; published online before print March 13, 2006. American College of Cardiology 2006 Scientific Sessions.) ACUITY Timing: Deferring GP IIb/IIIa blockers until PCI "safe and effective" strategy for ACS patients Mar 13, 2006 / But the overall results of the ACUITY trial, presented yesterday, suggest that GP IIb/IIIa blockers are not needed pancreatic cancer medication at all if bivalirudin is used as the antithrombotic agent. (American College of Cardiology 2006 Scientific Sessions.) Guidewire Mixed results for pancreatic cancer medication PFO closure in migraine cloud interpretation of MIST Mar 13, 2006 / Hopes that closing a PFO could vanquish migraine with aura sank here today, with the MIST I final results showing no difference in headache cessation between closure- and sham-treated migraineurs. Experts, however, say secondary findings are promising and blame an overly ambitious primary end point for the trial's failure. | pressrelease skyscape, being held from march 11 14, pre columbus american indians, explanation of american express membership rewards program, mexican american war mexico 1846, proud to be an american song lyrics, clinical practice, fujitsucomputer products of america, medical, american staffordshire terrier breeders nz, north american and american indians and three regions, nuclear medicine, |
|
| (i2 nuclear medicine Summit at the American College of Cardiology 2006 Scientific Sessions.) Guidewire Even in the DES era, avoid routine side-branch stenting at main-vessel PCI, says randomized study Mar 13, 2006 nuclear medicine / Greater procedural time and enzyme elevations with no evident clinical advantage at six months appear to dash hopes that drug-eluting stents would make bifurcation stenting more appealing in main-vessel lesions. (i2 Summit at the American College of Cardiology 2006 Scientific Sessions.) Cardiometabolic risk ASTEROID lands with a bang: High-dose rosuvastatin regresses coronary atherosclerosis Mar 13, nuclear medicine 2006 / UPDATED WITH COMMENTARY / While traditional thinking has viewed atherosclerosis as a progressive disease for which even the most active therapies can merely slow advancement, these new findings suggest there is potential for a more optimistic strategy, say investigators. |
![]() africa tour |
![]() namibia desert travel |
![]() tanzania travel |
![]() boat travel |
![]() bus travel |
![]() dating travel |
![]() egypt travel |
![]() europe travel |
![]() france tour |
![]() horse travel |
![]() last minute air ticket |
![]() car travel |
![]() travel bag |
![]() travel maps |